Sage Journals: Discover world-class research

Abstract

Bronchiolitis obliterans syndrome (BOS) is a severe pulmonary complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT) with limited therapeutic options once refractory to standard immunosuppression. We conducted a pilot study from January 2018 to December 2024, enrolling consecutive patients with BOS defined by NIH criteria who failed glucocorticoids and calcineurin inhibitors for ≥4 weeks. Sixteen patients received salvage therapy with ruxolitinib 5 mg twice daily and nintedanib 150 mg twice daily (RN cohort) in continuous 28-day cycles for up to six cycles, while 37 contemporary patients served as controls. At baseline, NIH lung scores in the RN cohort were 18.8% NIH 1, 18.8% NIH 2, and 62.5% NIH 3. The median number of treatment cycles was 3.5 (range, 1–6). At 3 months, 11 patients (68.8%) achieved ≥10% improvement in %FEV1 from baseline (median = 26.5%, range = 15.6%–58.2%). By NIH lung response criteria, the overall response rate (ORR) was 62.5% (12.5% complete response, 50.0% partial response) in the RN cohort versus 13.5% (5.4% complete, 8.1% partial) in controls. Notably, hematologic toxicities were less frequent with RN therapy than in controls. These findings suggest that low-dose ruxolitinib combined with nintedanib is an effective and well-tolerated salvage regimen for BOS after allo-HSCT and warrant confirmation in a prospective phase II study.

Keywords

bronchiolitis obliterans syndrome ruxolitinib nintedanib allo-HSCT cGvHD

Introduction

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is often complicated by transplant-related morbidities, among which graft-versus-host disease (GVHD) remains the most significant^1–6. Pulmonary manifestations of chronic GVHD are common and frequently culminate in bronchiolitis obliterans syndrome (BOS), a progressive and typically irreversible small airway disorder characterized by fibrotic obstruction of terminal bronchioles^7–9. The immunopathogenesis of BOS after allo-HSCT is not fully understood; however, it is thought to reflect the interplay between donor T and B lymphocytes, autoantibody production, and dysregulated fibrotic pathways, resembling features of autoimmunity and aberrant wound healing^10–12. Diagnosis of BOS is particularly challenging given its nonspecific clinical presentation and the absence of sensitive early biomarkers^13,14. First-line therapies, including systemic corticosteroids and calcineurin inhibitors (CNIs), which remain the mainstay of chronic GVHD management, often fail to provide durable benefit in patients with BOS. This therapeutic gap underscores the urgent need for novel and effective treatment strategies^15–21.

Several emerging interventions have been evaluated beyond supportive therapies, including inhaled corticosteroids and the fluticasone–azithromycin–montelukast (FAM) regimen. Second-line therapies are being introduced earlier in the disease course, often after a short nonresponsive course to systemic corticosteroids. These include Janus kinase (JAK) inhibitors such as ruxolitinib, Rho-associated kinase inhibitors such as belumosudil, and CSF1R inhibitors such as axatilimab^22–25. Among these, ruxolitinib has shown particular promise^23,26–32. In a recent phase II multicenter trial (NCT03674047), ruxolitinib at 10 mg twice daily achieved encouraging best lung-specific overall response rate (ORR) 34.7% and allowed most patients to taper or discontinue corticosteroids²⁷.

Parallel to immunomodulation, antifibrotic therapy has emerged as a promising strategy for inflammatory and fibrotic lung complications in the post-transplant setting. The STOP-BOS trial of pirfenidone in BOS demonstrated acceptable safety and signals of lung function stabilization in patients following allo-HSCT, with 41.3% of participants showing improvement in individual pulmonary function test trajectories, supporting the biological rationale for targeting fibrotic pathways^33,34.

Nintedanib, an intracellular tyrosine kinase inhibitor targeting multiple pro-fibrotic pathways, has been demonstrated to slow the decline of lung function in idiopathic pulmonary fibrosis and other fibrosing interstitial lung diseases^35–37. Preliminary clinical experience, including a case report of BOS improved with nintedanib, supports its potential role in the transplant setting³⁸.

Since the formal approval of ruxolitinib in China in 2017, we conducted a pilot study to evaluate the combination of low-dose ruxolitinib (5 mg orally twice daily) with nintedanib in patients with BOS refractory to glucocorticoids and CNIs after allo-HSCT. Our objective was to explore whether dual targeting of immune-mediated injury and fibrotic progression could provide a more effective salvage approach for this devastating complication.

Methods

Patients

From January 2018 to December 2024, consecutive patients with BOS who provided written informed consent were enrolled at Peking University People’s Hospital. The inclusion criteria were: (1) a diagnosis of BOS according to the EBMT guidelines; (2) refractoriness to at least 4 weeks of standard therapy with glucocorticoids and CNIs¹²; (3) not enrolled in investigational trials for chronic GVHD—such as those evaluating ROCK2, ROCK/JAK, or CSF1R inhibitors; and (4) no evidence of recurrent primary hematologic disease. Exclusion criteria included uncontrolled infections.

Study design

Enrolled eligible patients received salvage treatment with low-dose ruxolitinib (5 mg orally twice daily) combined with nintedanib (150 mg orally twice daily) continuously in 28-day cycles for up to six cycles (RN cohort). Contemporary patients with refractory BOS who did not enroll in RN cohort nor other cGvHD trials received the best available treatments (BATs) served as controls. The FAM regimen (fluticasone, azithromycin, and montelukast) was allowed as supportive therapy^4,6,12,39 (Fig. 1).

Figure 1.

Study design and patient enrollment flowchart. Schematic overview of the study design and patient selection. A total of 53 eligible patients were enrolled and divided into two cohorts: the RN cohort (ruxolitinib plus nintedanib, n = 16) and the control cohort (n = 37). Patients were evaluated for pulmonary function, treatment response, adverse events, and survival outcomes.

End points and definitions

The primary endpoint was the 3-month ORR after initiation of salvage treatment or best available therapies (BATs), defined as a ≥10% improvement in forced expiratory volume in 1 second (FEV₁). Secondary endpoints included the best overall response rate (BOR), 3-year non-relapse mortality (NRM), 3-year overall survival (OS), and treatment-related toxicities (TRTs). The start date for all endpoints was defined as the first day of salvage treatment or BATs. ORR was determined by the proportion of patients achieving a complete or partial response, based on the percentage change in FEV1 relative to baseline. BOR was defined as the best response achieved during treatment. NRM was defined as death without evidence of relapse or disease progression, while OS was defined as the time from treatment initiation to death from any cause. TRTs referred to adverse events attributed to the study regimen.

Statistical analysis

Categorical variables were compared using the chi-square test or Fisher’s exact test, as appropriate. Continuous variables were analyzed using either the independent-samples t-test or the Mann–Whitney U test, depending on the data distribution. Overall survival was estimated using the Kaplan–Meier method, and differences between groups were assessed by the log-rank test. The cumulative incidences of ORR, relapse, and NRM were evaluated within a competing risks framework. For ORR, relapse and death were treated as competing events. For relapse and NRM analyses, each event was considered in turn with the other treated as a competing risk. All statistical tests were two-sided, with P values <0.05 considered significant. Results are presented with 95% confidence intervals (95% CI). Analyses were performed using R software (version 4.4.3).

Results

Patient characteristics

Between January 2018 and December 2024, a total of 53 patients with BOS were enrolled, including 16 in the ruxolitinib plus nintedanib (RN) cohort and 37 who received BATs in the control group. Baseline characteristics are summarized in Table 1 and Fig. 2a. The median age of the entire cohort was 33 years (range, 7–57 years). Survivors had a median follow-up of 21.3 months after BOS diagnosis (range, 1.8–57.1 months) as of the data cutoff on 10 August 2025.

Table 1.

Characteristics of the enrolled patients.

	All patients (N = 53)	RN (N = 16)	Control (N = 37)	P value
Age median (range)	33 (7, 57)	36 (15, 56)	32 (7, 57)	0.352
Sex				0.766
Male	26	7 (43.8%)	19 (51.4%)
Female	27	9 (56.2%)	18 (48.6%)
Primary disease, n (%)				0.453
AML	26	12 (75%)	14 (37.8%)
ALL	11	2 (12.5%)	9 (24.3%)
MDS	4	2 (12.5%)	2 (5.4%)
Others	12	NA	12 (32.5%)
HCT-CI, n (%)				0.575
0–2	49	14 (87.5%)	35 (94.6%)
≥3	4	2 (12.5%)	2 (5.4%)
HLA-matching grade, n (%)				0.886
HLA matched	23	7 (43.8%)	16 (42.3%)
HLA Haploidentical	28	8 (50.0%)	20 (54.1%)
HLA 6/10	2	1 (6.2%)	1 (2.7%)
Donor-recipient sex match, n (%)				0.055
Male to male	11	4 (25%)	7 (18.9%)
Male to female	15	8 (50%)	7 (18.9%
Female to male	14	3 (18.8%)	11 (29.7%)
Female to female	13	1 (6.2%)	12 (32.4%)
ABO blood type				0.756
Match	32	9 (56.2%)	23 (62.2%)
Minor mismatch	9	4 (25%)	5 (13.5%)
Major mismatch	7	2 (12.5%)	5 (13.5%)
Bidirectional mismatch	5	1 (6.2%)	4 (10.8%)
Graft type				<0.001
BM + PB	30	1 (6.2%)	29 (78.4%)
PB alone	23	15 (93.8%)	8 (21.6%)
MNC counts in graft, median (range, ×10⁸/kg)	8.1 (5.4, 18.05)	8.18 (6.6, 18.05)	8.2 (5.4, 14.53)	0.673
CD34+ cell counts in graft, median (range, ×10⁶/kg)	2.82 (0.83, 8.2)	4.27 (1.5, 6.99)	2.66 (0.83, 8.2)	0.070
cGvHD-BOS				0.480
NIH Mild	7	3 (18.8%)	4 (10.8%)
NIH Moderate	15	3 (18.8%)	12 (32.4%)
NIH Severe	31	10 (62.5%)	21 (56.8%)
BOS Diagnosis months median (range, months)	10.8 (2.6, 35.1)	11.1 (3.2, 35.1)	10.9 (2.6, 32.3)	0.581
FEV1/Predicted % Baseline median (range, %)	36.8 (15.6, 79.5)	38.9 (22.4–70.3)	36 (15.6, 79.5)	0.257
BAT type		NA
CNIs			37 (100%)
MMF			10 (27%)
RUX			15 (41%)
Imatinib			3 (8%)
RN Cycles median (range, cycles)		3.5 (1–6)	NA

HCT-CI: hematopoietic cell transplantation comorbidity index; HLA: human leukocyte antigen; AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; MDS: myelodysplastic syndromes; MNC: mononuclear cells; NIH: National Institutes of Health; GvHD: graft-versus-host disease; FEV1: forced expiratory volume in 1 second; MMF: mycophenolate mofetil.

Figure 2.

Swimmer plot in the RN group. Treatment course and outcomes of the 16 patients in the RN cohort. Three deaths occurred during follow-up: two due to non-relapse mortality and one due to disease relapse. The swimmer plot illustrates treatment duration, timing of response, and long-term disease control.

The median interval from transplantation to BOS diagnosis was comparable between the RN and control cohorts, at 11.1 months (range, 3.2–35.1 months) versus 10.9 months (range, 2.6–32.3 months), respectively (P = 0.581). The median baseline FEV1 as a percentage of predicted was 38.9% (range, 22.4%–70.3%) in the RN cohort and 36.0% (range, 15.6%–79.5%) in the control cohort (P = 0.257). Based on NIH lung score, patients in the RN cohort were distributed as NIH 1 (18.8%), NIH 2 (18.8%), and NIH 3 (62.5%), while in the control cohort the distribution was NIH 1 (10.8%), NIH 2 (32.4%), and NIH 3 (56.8%) (P = 0.480) (Fig. 3a).

Figure 3.

Primary outcomes. (a) NIH lung score based on %FEV1 predicted at baseline in RN and control cohorts. (b) Three-month change in %FEV1 from baseline in the RN cohort. (c) Three-month NIH lung-specific overall response rate (ORR) in RN and control cohorts. (d) Best %FEV1 change from baseline in the RN cohort. (e) Best NIH lung-specific ORR in RN and control cohorts.

Patients in the RN cohort received a median of 3.5 treatment cycles (range, 1–6). In the control cohort, BATs primarily consisted of CNIs (100%), with additional use of mycophenolate mofetil (27%), ruxolitinib (41%), and imatinib (8%).

A direct comparison between ruxolitinib (n = 14) and RN (n = 16) was summarized in Supplemental Table 1. The two groups were well balanced with respect to baseline pulmonary disease severity, showing similar distributions of NIH BOS grades and comparable lung function at study entry. Median baseline FEV₁ was 38.9% (range, 22.4–70.3) in the RN group and 38.6% (range, 26.9–79.5) in the ruxolitinib group (P = 0.755) (Supplemental Figure 1A). The median interval from BOS diagnosis to treatment initiation was also similar between groups. Other baseline characteristics were generally comparable.

Key efficacy outcome parameters

At 3 months, 11 patients in the RN cohort (68.8%) achieved a ≥10% improvement in FEV1 compared with baseline, with a median increase of 26.5% (range, 15.6%–58.2%). Two patients experienced a ≥5% decline (Patient 2: baseline 38.2%, 3-month 31.0%; Patient 7: baseline 39.6%, 3-month 23.9%), and three patients remained stable (Patients 9, 15, and 16: baseline 60.0%, 68.9%, and 23.6%; 3-month 64.6%, 68.4%, and 23.6%, respectively) (Fig. 3c). Based on NIH lung response criteria, the 3-month ORR in the RN cohort was 62.5% (12.5% complete response [CR], 50.0% partial response [PR]), with 37.5% achieving stable disease and no patients showing progression. In contrast, the control cohort had an ORR of only 13.5% (5.4% CR, 8.1% PR), with 64.9% remaining stable and 21.6% worsening (Fig. 3). RN was associated with a numerically higher lung-specific response than ruxolitinib alone, with CR/PR rates of 12.5%/50.0% versus 7.1%/7.1%, respectively; stable disease occurred in 37.5% versus 57.1%, and lung function worsening in 0% versus 28.7% (Supplemental Figure 1B).

When the best FEV1 improvement during treatment was considered, 11 patients in the RN cohort demonstrated a ≥10% increase from baseline (median 30.6%, range, 15.6%–58.2%), 2 patients showed a ≥5% decline, and 3 remained stable. According to NIH lung response criteria, the best ORR in the RN cohort was 62.6% (18.8% CR, 43.8% PR), with 37.5% remaining stable and no patients worsening. The median best improvements in FEV1 during treatment for the NIH 1, 2, and 3 groups were 15.6%, 33.6%, and 21.6%, respectively (Supplemental Table 2). By comparison, the control cohort again achieved an ORR of only 13.5% (5.4% CR, 8.1% PR), with 64.9% (24/37) remaining stable and 21.6% (8/37) progressing (Fig. 3d, e and Supplemental Figure 1C).

Long-term survival outcomes

At 1 year, the overall survival (OS) rate was 83.5% (95% CI, 72.3–96.5) in the control cohort compared with 93.3% (95% CI, 81.5–100) in the RN cohort. At 3 years, OS declined to 60.4% (95% CI, 46.2–79.0) in the control group and 70.0% (95% CI, 45.9–100) in the RN group (P = 0.4). In the control cohort (n = 37), 16 events occurred, with the lower bound of the 95% CI for median OS at 29.4 months. In the RN cohort (n = 14), three events were recorded, with the lower bound at 19.7 months. Median OS was not reached in either group (Fig. 4a).

Figure 4.

Survival. (a) Kaplan–Meier curves for overall survival (OS) in RN and control cohorts. (b) Cumulative incidence of non-relapse mortality (NRM) in RN and control cohorts.

At 1 year, the non-relapse mortality (NRM) rate was 16.5% (95% CI, 6.6–30.3) in the control cohort versus 0% in the RN cohort. By 2 years, NRM increased to 24.9% (95% CI, 12.2–40.0) in the control cohort and 23.3% (95% CI, 2.8–55.1) in the RN cohort, with no further rise through 4 years in the RN group. At 3 years, cumulative NRM reached 31.1% (95% CI, 16.6–46.8) in the control cohort (P = 0.3) (Fig. 4b). Notably, two non-relapse deaths occurred in the RN cohort during the second year after discontinuation of RN regimen, both attributed to acute COVID-19 infection. Given the small sample size of the RN cohort (n = 16), these events had a disproportionate impact on cumulative NRM estimates and likely contributed to the apparent reduction in OS in this group.

Toxicities

Treatment-related toxicities are summarized in Table 2. Patients in the RN cohort received low-dose ruxolitinib, which was associated with a lower incidence of hematologic adverse events compared with the control cohort. Rates of any-grade anemia, thrombocytopenia, and neutropenia were 18.7%, 31.2%, and 18.7% in the RN cohort, versus 46.0%, 48.6%, and 21.6% in the control cohort, respectively. Grade ≥3 hematologic toxicities were also less frequent in the RN cohort: 6.0% for anemia and neutropenia and 18.7% for thrombocytopenia, compared with 16.2%, 10.8%, and 27.0% in the control cohort.

Table 2.

Toxicity profile of RN regimen versus best available therapies.

	RN (N = 16)				Control (N = 37)
	Any grade		>=Grade 3		Any grade		>=Grade 3
Anemia	3	18.7%	1	6%	17	45.9%	6	16.2%
Thrombocytopenia	5	31.2%	3	18.7%	18	48.6%	10	27.0%
Neutropenia	3	18.7%	1	6%	8	21.6%	4	10.8%
Diarrhea	4	25.0%	0	0%	6	16.2%	0	0%
Vomiting	5	31.2%	0	0%	7	18.9%	0	0%
Pneumonia	4	25.0%	1	6%	12	32.4%	4	10.8%
Bilirubin increase	4	25.0%	1	6%	16	43.2%	4	10.8%

Non-hematologic toxicities, including diarrhea, vomiting, and pneumonia, were generally comparable between the two cohorts and were predominantly low grade. Hyperbilirubinemia was observed in 25.0% of patients in the RN cohort and 43.0% in the control cohort, with grade ≥3 events occurring in 6.0% and 10.8% of patients, respectively.

Discussion

BOS is a devastating, progressive, late-onset pulmonary complication following allo-HSCT. It is characterized by irreversible airflow obstruction and is associated with poor prognosis. During the period when this study was initiated, therapeutic strategies for pulmonary chronic GVHD, including BOS, were highly heterogeneous across centers, and no universally accepted standard of care was established. Conventional immunosuppressive approaches at that time frequently included systemic or inhaled corticosteroids, sometimes combined with azithromycin and/or montelukast, as well as other agents used for chronic GVHD. However, these treatments were largely empirical and often associated with limited efficacy, substantial toxicities, and high failure rates, reflecting the incomplete understanding of the underlying immunopathological mechanisms of pulmonary chronic GVHD. Consequently, the development of novel, effective, and well-tolerated salvage therapies for BOS represents an urgent unmet clinical need^{7–10,38,40,41}.

This study is, to our knowledge, the first to evaluate the combination of ruxolitinib and nintedanib (RN regimen) for the treatment of steroid-refractory BOS. Ruxolitinib, a selective JAK1/2 inhibitor, exerts potent anti-inflammatory and immunomodulatory effects and has demonstrated clinical activity in chronic GVHD^23,26–30. Nintedanib, a multi-targeted tyrosine kinase inhibitor of VEGFR, FGFR, and PDGFR, has shown antifibrotic and anti-inflammatory efficacy in idiopathic pulmonary fibrosis and systemic sclerosis–related interstitial lung disease. While both agents have mechanistic plausibility and have been independently investigated in the settings of chronic GVHD and fibrotic lung disease, their concurrent use in BOS has not previously been reported. Given that BOS involves both immune-mediated inflammation and progressive airway fibrosis, the rationale for combining these two agents is strong and mechanistically complementary.

The efficacy of ruxolitinib in BOS has been explored in several clinical settings. Zhao et al.³⁰ firstly reported in a retrospective study that ruxolitinib as salvage therapy for BOS achieved a best overall response rate of 66.7%, with three patients (10.0%) attaining complete remission and 17 patients (56.7%) achieving partial remission. In the REACH3 trial of steroid-refractory chronic GVHD, ruxolitinib 10 mg twice daily achieved a superior ORR at week 24 compared with control (49.7% vs. 25.6%), but the lung-specific benefit was limited, with improvement observed in only 8.6% of patients with pulmonary involvement²⁹. More recently, a multicenter phase II trial (NCT03674047) in BOS reported a best lung-specific ORR of 34.7% among 49 participants (16.3% complete responses and 18.4% partial responses)²⁷. These findings indicate that while ruxolitinib has activity in BOS, its efficacy as monotherapy remains modest, particularly for fibrotic airway disease.

Evidence for the use of nintedanib in BOS is even more limited. Nintedanib has been extensively validated in idiopathic pulmonary fibrosis and other progressive fibrosing interstitial lung diseases, where it consistently slows functional decline³⁵. Of particular note, a single case report described significant improvement in lung function in a post-transplant BOS patient treated with nintedanib monotherapy, including a marked increase in FEV1³⁸. While anecdotal, this observation supports the potential role of nintedanib in managing fibrotic airway disease after transplantation, although robust clinical evidence is still lacking.

In contrast to the monotherapy approaches described above, our study demonstrates that combining low-dose ruxolitinib with nintedanib can simultaneously address both the inflammatory and fibrotic components of BOS pathophysiology. This dual-targeted strategy was associated not only with meaningful improvements in lung function but also with an improved safety profile. Hematologic toxicities were reduced in the RN cohort, with any-grade anemia, thrombocytopenia, and neutropenia occurring in 18.7%, 31.2%, and 18.7% of patients, respectively, compared with 46.0%, 48.6%, and 21.6% in the control group. Rates of grade ≥3 hematologic adverse events were likewise lower in the RN cohort. Collectively, these findings highlight the therapeutic potential of a dose-optimized, multi-targeted combination regimen as a promising salvage strategy for BOS.

The RN regimen demonstrated encouraging pulmonary benefits, with 68.8% of patients achieving a ≥10% increase in FEV1 at 3 months and an NIH-defined lung-specific ORR of 62.5%, compared with 13.5% in the control group. No patients in the RN cohort deteriorated, whereas about one-fifth in the control group showed worsening disease, suggesting that this regimen may effectively stabilize or even reverse pulmonary decline in steroid-refractory BOS. We acknowledge that the ORR observed in the ruxolitinib-alone cohort in our study was lower than that reported in the phase II trial²⁷, in which an overall lung response rate of 34.7% (including 16.3% CR and 18.4% PR) was achieved. This discrepancy may be explained, at least in part, by differences in treatment exposure and study design. In the phase II trial, patients were prospectively treated with ruxolitinib at a standardized dose of 10 mg twice daily for up to 12 months, whereas in our retrospective real-world cohort, the median duration of ruxolitinib therapy was approximately 4 months, which may have limited the opportunity to achieve maximal pulmonary response.

Regarding long-term survival, the RN cohort showed a lower 1-year NRM rate (0.0%) compared with 16.5% in the control group. Two deaths in the RN cohort occurred during the second year, both related to acute COVID-19 infection, which disproportionately influenced cumulative NRM estimates given the small sample size (n = 16). By 3 years, cumulative NRM was 31.1% in the control group versus 23.3% in the RN group, with no statistically significant difference. These findings emphasize the need for cautious interpretation of long-term outcomes in small cohorts, particularly when external factors such as infections may confound survival analyses.

Although the results of this study are encouraging, several limitations must be acknowledged. The trial was conducted at a single center with a relatively small sample size, which limits the application of propensity score matching or weighting approaches, as such methods would have further reduced the effective number of analyzable patients and compromised statistical power. Consequently, potential baseline imbalances between treatment groups cannot be fully excluded. Notably, the proportion of patients with NIH Score 1 was higher in the RN cohort, suggesting possible enrichment for milder disease at baseline. These imbalances may have influenced the observed outcomes and should be interpreted with caution. Treatment duration was not uniform, ranging from three to six cycles, and follow-up intervals were variable. In addition, pulmonary function was assessed over a relatively short observation window. Therefore, our findings should be regarded as hypothesis-generating and warrant validation in larger, prospective studies with appropriate baseline adjustment or stratified design.

Conclusions

Our pilot study is the first to demonstrate that concurrent administration of low-dose ruxolitinib and nintedanib is a feasible, well-tolerated, and potentially effective salvage therapy for BOS. By simultaneously targeting immune-mediated inflammation and progressive fibrosis, this dual-target regimen may provide synergistic clinical benefit. The favorable safety profile observed with the reduced ruxolitinib dose (5 mg twice daily) underscores its suitability for post-transplant patients. Future prospective phase II trials with larger sample sizes and incorporation of quality-of-life assessments are warranted to validate these finding.

Supplemental Material

sj-docx-1-cll-10.1177_09636897261438731 – Supplemental material for Salvage nintedanib plus low-dose ruxolitinib therapy for bronchiolitis obliterans syndrome refractory to calcineurin inhibitors and glucocorticoids after allogeneic transplantation

Supplemental material, sj-docx-1-cll-10.1177_09636897261438731 for Salvage nintedanib plus low-dose ruxolitinib therapy for bronchiolitis obliterans syndrome refractory to calcineurin inhibitors and glucocorticoids after allogeneic transplantation by Ya Luo, Ying Wu, Qiu-Sha Huang, Xian-Ying Yin, Qian-Nan Shang, Yi-Han Yang, Ao-Ran Zhang, Tong Su, Xiao-Han Su, Su-Xuan Liu, Zheng-Li Xu, Jing Liu, Xiao-Dong Mo, Yu-Qian Sun, Yu Wang and Meng Lv in Cell Transplantation

Footnotes

Acknowledgements

We sincerely thank Prof. Xiao-Jun Huang, Prof. Xiao-Hui Zhang, and Prof. Lan-Ping Xu for their supervision of patient care and consultation throughout the study.

Authors’ Note

Part of the data included in this manuscript was previously presented as an oral presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 2024.

ORCID iD

Meng Lv

Ethical Considerations

The study protocol was approved by the Ethics Committee of Peking University People’s Hospital (2017PHB221) on 2 December 2017.

Consent for Publication

Written informed consent for publication of clinical data was obtained from all participants.

Author Contributions

ML led the clinical trial, oversaw patient enrollment, performed data analysis, and drafted the manuscript. YL collected and curated the data and contributed to manuscript writing. YW and Q-SH were responsible for data collection. All other authors contributed to patient care and clinical management. All authors reviewed the manuscript and approved the final version for publication.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Beijing Research Ward Excellence Program (BRWEP2024W134080100), National key research and development plan of China (2021YFA1100902), Peking University People’s Hospital (RZ2024-01), and Joint Research Project of the Shijiazhuang-Peking University Cooperation Program.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data Availability Statement

The datasets used and/or analyzed in the current study are available from the corresponding authors on reasonable request.

Supplemental Material

Supplemental material for this article is available online.

Statement of Human and Animal Rights

This article does not contain any studies with human or animal subjects.

Statement of Informed Consent

There are no human subjects in this article and informed consent is not applicable.

References

Malard

Mohty

Updates in chronic graft-versus-host disease management. Am J Hematol. 2023;98(10):1637–44.

Mohseni

Mahdavi Sharif

Behfar

Modaresi

Shirzadi

Mardani

Jafari

Nikfetrat

Hamidieh

AA.

Evaluation of safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells in pediatric bronchiolitis obliterans syndrome (BoS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Stem Cell Res Ther. 2023;14(1):256.

Olivieri

Manfredi

Postacchini

Tedesco

Leoni

Gabrielli

Rambaldi

Bacigalupo

Olivieri

Pomponio

Consensus recommendations for improvement of unmet clinical needs–the example of chronic graft-versus-host disease: a systematic review and meta-analysis. Lancet Haematol. 2015;2(7):e297–305.

Penack

Marchetti

Ruutu

Aljurf

Bacigalupo

Bonifazi

Ciceri

Cornelissen

Malladi

Duarte

Giebel

, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. The Lancet Haematology. 2020;7(2):e157–67.

Baumrin

Loren

Falk

Mays

Cowen

EW.

Chronic graft-versus-host disease. Part I: epidemiology, pathogenesis, and clinical manifestations. J Am Acad Dermatol. 2024;90(1):1–16.

Penack

Marchetti

Aljurf

Arat

Bonifazi

Duarte

Giebel

Greinix

Hazenberg

Kroger

Mielke

, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024;11(2):e147–59.

Glanville

Benden

Bergeron

Cheng

G-S

Gottlieb

Lease

Perch

Todd

Williams

Verleden

GM.

Bronchiolitis obliterans syndrome after lung or haematopoietic stem cell transplantation: current management and future directions. ERJ Open Research. 2022;8(3):00185–2022.

Grønningsæter

Tsykunova

Lilleeng

Ahmed

Bruserud

Reikvam

Bronchiolitis obliterans syndrome in adults after allogeneic stem cell transplantation-pathophysiology, diagnostics and treatment. Expert Rev Clin Immunol. 2017;13(6):553–69.

Todd

Palmer

SM.

Bronchiolitis obliterans syndrome. Chest. 2011;140(2):502–508.

10.

Shanthikumar

Gower

Srinivasan

Rayment

Robinson

Bracken

Stone

Das

Barochia

Charbek

Tamae-Kakazu

, et al. Detection of bronchiolitis obliterans syndrome after pediatric hematopoietic stem cell transplantation: an official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2024;210(3):262–80.

11.

Bergeron

Cheng

GS.

Bronchiolitis obliterans syndrome and other late pulmonary complications after allogeneic hematopoietic stem cell transplantation. Clin Chest Med. 2017;38(4):607–21.

12.

Bos

Murray

Marchetti

Cheng

Bergeron

Wolff

Sander

Sharma

Badawy

Peric

Piekarska

, et al. ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults. Eur Respir J. 2024;63(3).

13.

Brothers

Malhotra

Andrews

Smith

SR.

Graft-versus-host disease: an update on functional implications and rehabilitation interventions. Curr Oncol Rep. 2023;25(3):145–50.

14.

Jagasia

Greinix

Arora

Williams

Wolff

Cowen

Palmer

Weisdorf

Treister

Cheng

Kerr

, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 2015;21(3):389–401.

15.

Zeiser

Novel approaches to the treatment of chronic graft-versus-host disease. J Clin Oncol. 2023;41(10):1820–25.

16.

Huang

Han

Chen

Zhao

Zhu

Wang

Zhang

, et al. Clinical risk factors and prognostic model for patients with bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2024;59(2):239–46.

17.

Liu

Zhang

Chen

Han

Wang

Liu

, et al. Risk factors for bronchiolitis obliterans syndrome in allogeneic hematopoietic stem cell transplantation. Chin Med J. 2013;126(13):2489–94.

18.

Wang

Huang

XJ.

Myeloid-derived suppressor cells in hematological malignancies: friends or foes. J Hematol Oncol. 2019;12(1):105.

19.

Wang

Chang

Zhao

Zhang

Sun

Wang

Suo

Zhou

Liu

, et al. Early myeloid-derived suppressor cells (HLA-DR(-)/(low)CD33(+)CD16(-)) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT. J Hematol Oncol. 2019;12(1):31.

20.

Gorin

Huang

XJ.

A vision for the future of allogeneic hematopoietic stem cell transplantation in the next decade. Sci Bull. 2022;67(19):1921–24.

21.

Shen

Development of allogeneic hematopoietic stem cell transplantation in 2022: regenerating “Groot” to heal the world. Innovation. 2023;4(1):100373.

22.

Miklos

Abu Zaid

Cooney

Albring

Flowers

Skarbnik

Yakoub-Agha

B-S

Bruno

Waller

Yared

, et al. Ibrutinib for first-line treatment of chronic graft-versus-host disease: results from the randomized phase III iNTEGRATE study. J Clin Oncol. 2023;41(10):1876–87.

23.

Pusic

Lee

Veeraputhiran

Minor

DiPersio

JF.

Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease. Bone Marrow Transplant. 2024;59(2):282–84.

24.

Kitko

Arora

DeFilipp

Zaid

Di Stasi

Radojcic

Betts

Coussens

Meyers

Qamoos

Ordentlich

, et al. Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: results of a phase I/II study. J Clin Oncol. 2023;41(10):1864–75.

25.

Cao

Huo

Jiang

Lei

Zhao

Chen

Guo

Huang

Zhang

, et al. Xenopax for the treatment of steroid-refractory acute graft-versus-host disease: the RELAX study. Mil Med Res. 2025;12(1):63.

26.

Baccelli

Gottardi

Muratore

Leardini

Grasso

Gori

Belotti

Prete

Masetti

Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis. Bone Marrow Transplant. 2024;59(6):765–76.

27.

DeFilipp

Kim

Cheng

Hamilton

Chhabra

Hamadani

Sandhu

Perez

Lee

Brennan

Garrelts

, et al. A phase 2 multicenter trial of ruxolitinib to treat bronchiolitis obliterans syndrome after allogeneic HCT. Blood Adv. 2025;9(2):244–53.

28.

Meng

G-Q

Wang

Y-N

Wang

J-S

Wang

Ruxolitinib treatment for bronchiolitis obliterans syndrome following hematopoietic stem cell transplant in a patient with primary hemophagocytic lymphohistiocytosis. Chin Med J. 2021;134(13):1624–25.

29.

Zeiser

Polverelli

Ram

Hashmi

Chakraverty

Middeke

Musso

Giebel

Uzay

Langmuir

Hollaender

, et al. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. New Engl J Med. 2021;385(3):228–38.

30.

Zhao

OuYang

Shi

Luo

Tan

Lai

Liu

Huang

Salvage therapy with low-dose ruxolitinib leads to a significant improvement in bronchiolitis obliterans syndrome in patients with cGVHD after allogeneic hematopoietic stem cell transplantation. Front Pharmacol. 2021;12:668825.

31.

Zhao

Liu

Zhang

Wang

Chen

Liu

Huang

XD.

Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide. Ann Hematol. 2021;100(1):169–80.

32.

Fan

Huo

Yang

Shen

XD.

Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: a meta-analysis. Front Immunol. 2022;13:954268.

33.

Matthaiou

Sharifi

O’Donnell

Chiu

Owyang

Chatterjee

Turk

Johnston

Brondstetter

Morris

Cheng

, et al. The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial. Bone Marrow Transplant. 2022;57(8):1319–26.

34.

Sharifi

Moss

Musa

Bell

O’Donnell

Borges

Matthaiou

Johnston

Galban

Sheshadri

Yanik

, et al. Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease. Blood Adv. 2025;9(19):5024–37.

35.

Flaherty

Wells

Cottin

Devaraj

Walsh

SLF

Inoue

Richeldi

Kolb

Tetzlaff

Stowasser

Coeck

, et al. Nintedanib in progressive fibrosing interstitial lung diseases. New Engl J Med. 2019;381(18):1718–27.

36.

Richeldi

Du Bois

Raghu

Azuma

Brown

Costabel

Cottin

Flaherty

Hansell

Inoue

Kim

, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. New Engl J Med. 2014;370(22):2071–82.

37.

Maher

TM.

Interstitial lung disease: a review. JAMA. 2024;331(19):1655.

38.

Tang

Dong

Liu

Nintedanib in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. Chest. 2020;158(3):e89–91.

39.

Cheng

Storer

Chien

Jagasia

Hubbard

Burns

Pidala

Palmer

Johnston

Mayer

, et al. Lung function trajectory in bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplant. Ann Am Thorac Soc. 2016;13(11):1932–39.

40.

Hakim

Cooke

Pavletic

Khalid

Williams

Hashmi

SK.

Diagnosis and treatment of bronchiolitis obliterans syndrome accessible universally. Bone Marrow Transplant. 2019;54(3):383–92.

41.

Kordjazy

Amini

A review of the therapeutic potential of the cysteinyl leukotriene antagonist Montelukast in the treatment of bronchiolitis obliterans syndrome following lung and hematopoietic-stem cell transplantation and its possible mechanisms. Ther Adv Respir Dis. 2024;18:17534666241232284.